Clinical Trials Logo

Oral Mucositis clinical trials

View clinical trials related to Oral Mucositis.

Filter by:

NCT ID: NCT00323518 Completed - Oral Mucositis Clinical Trials

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Start date: May 2006
Phase: Phase 2
Study type: Interventional

CG53135-05 (velafermin), a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem cell transplant. The objective of this Phase II trial is to confirm the safety and efficacy of CG53135-05 (velafermin) when administered as a single dose to patients at risk for developing oral mucositis.

NCT ID: NCT00289003 Completed - Oral Mucositis Clinical Trials

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

Start date: October 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy. Hypothesis: Soluble beta-1,3/1,6-glucan will through its immunomodulating activities prevent oral mucositis

NCT ID: NCT00267046 Completed - Sarcoma Clinical Trials

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Start date: December 2005
Phase: Phase 2
Study type: Interventional

Primary: 1. To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis (OM) in patients with sarcoma receiving multicycle chemotherapy. 2. To evaluate the pharmacokinetics (PK) of palifermin when given pre chemotherapy. 3. To evaluate the safety profile of palifermin when combined with multicycle chemotherapy. Exploratory: 1. To evaluate the biologic effect of palifermin on oral mucosa. 2. To investigate potential biomarker development by biochemical analysis in blood cells, serum, and plasma. 3. To investigate the effects of genetic variation in mucositis genes, drug metabolism genes, and drug target genes on patient response to the treatment regimen.

NCT ID: NCT00230191 Completed - Clinical trials for Head and Neck Cancer

Safety and Efficacy of RK0202 in Oral Mucositis

Start date: January 2003
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis in subjects receiving radiation therapy for head and neck cancer. Concurrent chemotherapy is not allowed in the study.